Hypotension in Multiple Myeloma: Causes and Clinical Approach
Hypotension in a patient with multiple myeloma can result from multiple disease-specific and treatment-related mechanisms, including autonomic neuropathy (autoimmune autonomic ganglionopathy), systemic capillary leak syndrome, infection/sepsis, medication effects (particularly during autologous stem cell transplant), and volume depletion from renal impairment or hypercalcemia.
Disease-Specific Causes
Autoimmune Autonomic Ganglionopathy
Multiple myeloma can present with paraneoplastic autoimmune autonomic ganglionopathy, manifesting as orthostatic hypotension. This occurs through anti-ganglionic nicotinic acetylcholine receptor (anti-gAChR) antibodies 1. The key clinical feature is orthostatic hypotension that improves with myeloma treatment, even with partial disease response. Check anti-gAChR antibodies if orthostatic symptoms are prominent.
Systemic Capillary Leak Syndrome
This rare but life-threatening complication presents with sudden severe edema, hypotension, elevated hematocrit, and decreased serum albumin, indicating capillary hyperpermeability 2. Look for the triad of hypotension, hemoconcentration, and hypoalbuminemia occurring acutely. This has been documented specifically with IgG kappa myeloma.
Treatment-Related Causes
Peri-Transplant Orthostatic Hypotension
During autologous stem cell transplantation, 64% of patients develop orthostatic hypotension at a median of 7 days post-transplant 3. Risk factors include:
- Weight loss ≥0.5% per day
- White race
- Gabapentin use
- Antihypertensive medications
Protective factors include antihistamines and proton pump inhibitors 3. Monitor orthostatic vitals daily during the peri-transplant period and hold antihypertensives prophylactically.
Infection and Sepsis
Infections are the main cause of death in patients with myeloma 4. Hypotension from sepsis is common due to T-cell immune dysfunction, B-cell compartment changes with hypogammaglobulinemia, and treatment-induced neutropenia 4. The 2025 EHA-EMN guidelines emphasize prophylactic levofloxacin during the first 12 weeks of treatment for newly diagnosed myeloma, which reduced febrile episodes or death by 34% (HR 0.66) 4.
Complications Contributing to Hypotension
Renal Impairment
Present in up to 20% of patients at diagnosis 4. Renal failure causes volume depletion and electrolyte abnormalities contributing to hypotension. The IMWG provides specific dosing recommendations for lenalidomide based on creatinine clearance 4. Bortezomib requires no dose adjustment and accelerates free light chain clearance, making it advantageous in renal impairment 5.
Anemia and Bone Marrow Failure
Anemia occurs commonly through iron-restricted erythropoiesis from hepcidin upregulation 4. Grade 3-4 anemia occurs in 3-19% with novel agents 5. Severe anemia reduces oxygen delivery and can contribute to hypotensive symptoms. Use erythropoiesis-stimulating agents and optimize iron supplementation if myeloma-related anemia persists despite chemotherapy 5.
Hypercalcemia
Though not explicitly detailed in the provided guidelines, hypercalcemia (the "C" in CRAB criteria) causes volume depletion through osmotic diuresis, directly contributing to hypotension.
Medication-Induced Hypotension
Proteasome Inhibitors and Immunomodulatory Drugs
Current myeloma therapies including bortezomib, carfilzomib, lenalidomide, and pomalidomide cause cytopenias that can contribute to cardiovascular instability 5. Carfilzomib specifically has known cardiovascular toxicity that may include hypotension.
Antihypertensive Medications
In the peri-transplant setting, continuation of antihypertensives significantly increases orthostatic hypotension risk 3. Review and hold these medications during high-risk periods.
Clinical Pitfalls
- Don't assume orthostatic hypotension is simply volume depletion—consider paraneoplastic autonomic neuropathy, especially if symptoms preceded or occurred early in myeloma diagnosis
- Don't overlook capillary leak syndrome—the combination of hypotension with edema and hemoconcentration is counterintuitive but diagnostic
- Don't continue antihypertensives reflexively during ASCT—they are an independent risk factor for peri-transplant orthostatic hypotension
- Don't delay infection workup—sepsis is the leading cause of death and requires immediate evaluation when hypotension develops
Algorithmic Approach
- Assess timing: New diagnosis vs. during treatment vs. peri-transplant
- Check orthostatic vitals: If positive, consider autonomic neuropathy (check anti-gAChR antibodies) vs. volume depletion vs. medication effect
- Evaluate for infection: Blood cultures, imaging if febrile or neutropenic
- Review medications: Hold antihypertensives, gabapentin if orthostatic; assess for cardiotoxic agents
- Check labs: CBC (anemia, neutropenia), comprehensive metabolic panel (renal function, calcium), albumin, hematocrit
- If edema + hypotension + high hematocrit: Consider capillary leak syndrome
- If peri-transplant: Expect orthostatic hypotension; monitor weight loss, hold antihypertensives prophylactically